Net profit of Jenburkt Pharmaceuticals rose 38.18% to Rs 7.42 crore in the quarter ended June 2024 as against Rs 5.37 crore during the previous quarter ended June 2023. Sales rose 11.51% to Rs 32.54 crore in the quarter ended June 2024 as against Rs 29.18 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales32.5429.18 12 OPM %28.5523.85 - PBDT10.597.93 34 PBT10.077.43 36 NP7.425.37 38 Powered by Capital Market - Live News

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live News

Jenburkt Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 July 2024.Powered by Capital Market - Live News

Jenburkt Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 28 May 2024, inter alia, have recommended the final dividend of Rs 15.3 per equity Share (i.e. 153%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Jenburkt Pharmaceuticals rose 24.09% to Rs 7.88 crore in the quarter ended March 2024 as against Rs 6.35 crore during the previous quarter ended March 2023. Sales rose 10.34% to Rs 38.84 crore in the quarter ended March 2024 as against Rs 35.20 crore during the previous quarter ended March 2023.For the full year,net profit rose 5.57% to Rs 25.98 crore in the year ended March 2024 as against Rs 24.61 crore during the previous year ended March 2023. Sales rose 3.82% to Rs 141.97 crore in the year ended March 2024 as against Rs 136.75 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales38.8435.20 10 141.97136.75 4 OPM %25.3621.25 -23.3322.21 - PBDT10.988.66 27 37.5235.12 7 PBT10.368.07 28 35.1832.86 7 NP7.886.35 24 25.9824.61 6 Powered by Capital Market - Live News